Open an account

Theriva Biologics

TOVX · NYSE American

$0.208+$0.0033 (+1.61%)TodayMarket closed ·
Prev close $0.2047

About TOVX

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 15 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Employees
15
Headquarters
Rockville, Maryland
Listed
Feb 12, 1993
Sector
Health Care
Industry
Biotechnology
Website
therivabio.com

TOVX key statistics

Market cap
9.55M
Price-earnings ratio
0.28
Dividend yield
—
Average volume
469.63K
Volume
331.50K
Open price
$0.209
High today
$0.214
Low today
$0.204
52 Week high
$0.85
52 Week low
$0.1628

Theriva Biologics (TOVX) at a glance

Theriva Biologics (TOVX) last traded at $0.208, with a market cap of 9.55M and a price-to-earnings ratio of 0.28.

Today the stock has traded between $0.204 and $0.214. The current price is 2.0% above the day's low and 2.8% below its high.

Volume so far is 331.50K shares, below the average of 469.63K shares a day.

Over the past year Theriva Biologics has ranged from $0.1628 to $0.85, and now sits 7% of the way up that range.

Theriva Biologics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.051.

The average analyst price target is $2.55, 1126.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $2.55
Low
$1.01
Now
$0.208
High
$4.20

TOVX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 38.3% on average.

  1. Q3 FY24: reported -$6.81 per share against an estimate of -$6.38
  2. Q4 FY24: reported -$3.30 per share against an estimate of -$6.49
  3. Q1 FY25: reported -$1.55 per share against an estimate of -$4.27
  4. Q2 FY25: reported -$0.57 per share against an estimate of -$0.9333
  5. Q3 FY25: reported -$0.45 per share against an estimate of -$0.7701
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.4437
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.051
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.051

TOVX news

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Dylan Berman

    Why Is Theriva Stock Gaining Monday?

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    $30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Dow Dips Over 100 Points; US Crude Oil Inventories Surge

  • Avi Kapoor

    Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings

Similar companies

Companies in the same industry as Theriva Biologics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.